Press release
Open-Angle Glaucoma Market Forecast to Grow at 6.4% CAGR, Reaching USD 13.6 Billion by 2034
Open-Angle Glaucoma Market
Open-angle glaucoma (OAG) is the most common form of glaucoma, accounting for nearly 90% of all cases globally. Characterized by progressive optic nerve damage often linked to elevated intraocular pressure (IOP), the disease develops slowly and is typically asymptomatic until significant vision loss occurs. This makes OAG a silent but severe global health challenge. Left untreated, it can cause irreversible blindness, making early diagnosis and long-term management essential.
The global open-angle glaucoma market is gaining traction as rising prevalence, aging populations, and advances in treatment drive demand for innovative solutions. From pharmacological therapies and laser treatments to minimally invasive surgical approaches, the industry is rapidly evolving. By 2034, the market is expected to witness strong expansion, supported by drug pipeline advancements, improved patient awareness, and healthcare investments worldwide.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72266
Market Overview
• Market Size (2024): USD 7.4 billion
• Forecast (2034): USD 13.6 billion
• CAGR (2024-2034): ~6.4%
Key Highlights:
• Growing global prevalence of OAG, particularly among aging populations.
• Increased demand for intraocular pressure-lowering drugs and novel formulations.
• Advances in minimally invasive glaucoma surgeries (MIGS) driving adoption.
• Rising awareness through global eye health initiatives and screening programs.
Leading Players: Novartis AG, Allergan (AbbVie Inc.), Alcon Inc., Bausch + Lomb, Pfizer, Santen Pharmaceutical, Aerie Pharmaceuticals, and Teva Pharmaceuticals are among the dominant players. Emerging companies are contributing by developing sustained-release implants and innovative ocular drug delivery systems.
Key Drivers: Increasing patient pool, new therapeutic options, and better diagnostic technologies.
Key Challenges: High treatment costs, patient non-adherence to eye drop regimens, and underdiagnosis in developing regions.
Segmentation Analysis
By Product
• Prostaglandin Analogs
• Beta Blockers
• Alpha Agonists
• Carbonic Anhydrase Inhibitors
• Combination Drugs
• Minimally Invasive Glaucoma Surgery (MIGS) Devices
• Laser Systems
By Platform
• Prescription Drugs
• Over-the-Counter Solutions (supportive eye care products)
• Surgical Implants and Devices
By Technology
• Topical Ophthalmic Formulations (eye drops)
• Sustained-Release Drug Delivery (implants, inserts)
• Laser Therapy (selective laser trabeculoplasty, argon laser trabeculoplasty)
• Minimally Invasive Surgery (MIGS)
By End Use
• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers
• Retail and Online Pharmacies
By Application
• First-Line Therapy
• Adjunctive Therapy
• Surgical/Device-Based Treatment
Summary: The OAG market is currently dominated by prostaglandin analogs and beta blockers, which serve as the first-line therapy. However, the rise of sustained-release implants, MIGS devices, and combination therapies is reshaping treatment strategies, offering longer-term efficacy and improved adherence.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72266/open-angle-glaucoma-market
Regional Analysis
North America
• Largest market share due to high disease prevalence, advanced healthcare infrastructure, and strong pharmaceutical presence.
• The U.S. leads with adoption of innovative drug delivery systems and minimally invasive surgeries.
• Favorable reimbursement policies supporting widespread patient access.
Europe
• High screening and diagnosis rates in Germany, UK, France, and Italy.
• Expanding uptake of MIGS and laser therapies in hospital and outpatient settings.
• Strong presence of global ophthalmic leaders contributing to innovation.
Asia-Pacific
• Fastest-growing region, driven by large patient pool and increasing awareness.
• Japan and China lead in innovation, with India showing rapid growth in diagnosis and treatment adoption.
• Expanding access through online pharmacies and government-led vision health programs.
Middle East & Africa
• Rising prevalence in urban populations, with GCC nations investing in advanced ophthalmology infrastructure.
• Limited access in low-income countries but increasing demand for affordable generics.
• Growing role of medical tourism in the Middle East for glaucoma treatments.
Latin America
• Brazil and Mexico are primary growth drivers.
• Increasing healthcare investment in ophthalmology facilities and screening initiatives.
• Entry of cost-effective generics expanding treatment accessibility.
Summary: North America and Europe remain leaders due to innovation and established healthcare systems, but Asia-Pacific is emerging as the fastest-growing region, benefiting from large populations, rising awareness, and rapid healthcare expansion.
Market Dynamics
Growth Drivers
1. Aging Populations: OAG prevalence rises with age, fueling demand for treatments.
2. Technological Advances: MIGS devices and sustained-release implants improving patient adherence and outcomes.
3. Global Awareness Campaigns: WHO and national programs increasing early detection.
4. Expanding Access: Growing online pharmacy and e-health platforms broadening availability.
Challenges
1. Patient Non-Adherence: Daily eye drop regimens lead to compliance issues.
2. High Cost of Advanced Treatments: Surgical devices and implants remain expensive.
3. Limited Awareness in Emerging Economies: Underdiagnosis and lack of ophthalmologists remain barriers.
4. Side Effects of Drugs: Long-term use of certain medications may cause systemic or ocular complications.
Latest Trends
• Sustained-Release Drug Delivery: Long-acting implants reducing treatment burden.
• Rise of MIGS: Safer, quicker surgical interventions gaining global adoption.
• Digital Monitoring: AI-driven diagnostic tools and mobile applications supporting disease management.
• Biosimilars and Generics: Expanding access to cost-effective alternatives.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72266
Competitor Analysis
Major Players:
• Novartis AG
• Allergan (AbbVie Inc.)
• Alcon Inc.
• Bausch + Lomb
• Pfizer Inc.
• Santen Pharmaceutical Co., Ltd.
• Aerie Pharmaceuticals
• Teva Pharmaceuticals
• Glaukos Corporation
• Carl Zeiss Meditec AG
Competitive Dynamics:
The open-angle glaucoma market is a blend of established pharmaceutical leaders focusing on advanced drug formulations and medical device innovators driving surgical breakthroughs. Strategic collaborations, acquisitions, and R&D investments are shaping the competitive landscape. Companies are racing to develop long-acting therapies and next-generation MIGS devices to secure market share in this rapidly evolving field.
Conclusion
The open-angle glaucoma market is projected to expand from USD 7.4 billion in 2024 to USD 13.6 billion by 2034, growing at a CAGR of ~6.4%. The expansion is fueled by demographic aging, improved diagnosis, and the emergence of innovative treatment solutions.
Although challenges such as high treatment costs and patient non-adherence persist, the industry outlook is highly positive. Advances in sustained-release drug delivery, MIGS devices, and AI-powered monitoring tools are set to redefine disease management.
This report is also available in the following languages : Japanese (開放隅角緑内障市場), Korean (개방각녹내장 시장), Chinese (开角型青光眼市场), French (Marché du glaucome à angle ouvert), German (Markt für Offenwinkelglaukom), and Italian (Mercato del glaucoma ad angolo aperto), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72266
Our More Reports:
Neurotrophic Keratitis Market
https://exactitudeconsultancy.com/reports/72236/neurotrophic-keratitis-market
Myopic Macular Degeneration (MMD) Market
https://exactitudeconsultancy.com/reports/72234/myopic-macular-degeneration-mmd-market
Limbal Stemhttps://exactitudeconsultancy.com/reports/72232/limbal-stem-cells-deficiency-lsd-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Open-Angle Glaucoma Market Forecast to Grow at 6.4% CAGR, Reaching USD 13.6 Billion by 2034 here
News-ID: 4193860 • Views: …
More Releases from Exactitude Consultancy
Optic Atrophy Market Projected to Grow at 6.8% CAGR, Reaching USD 1.2 Billion by …
Introduction
Optic atrophy, a condition characterized by the degeneration of optic nerve fibers leading to progressive vision loss, remains a serious global health challenge. Unlike other eye diseases, optic atrophy is not a single disorder but a manifestation of underlying conditions such as glaucoma, ischemia, multiple sclerosis, hereditary disorders, or trauma. Its complex etiology and irreversible nature make it difficult to treat, pushing research efforts toward neuroprotection, regenerative therapies, and early…
Neovascular Age-Related Macular Degeneration Market to Grow at 6.2% CAGR, Reachi …
Introduction
Neovascular age-related macular degeneration (nAMD), also known as "wet AMD," is a leading cause of irreversible vision loss among older adults worldwide. Unlike dry AMD, which progresses slowly, nAMD is characterized by abnormal blood vessel growth under the retina, leading to rapid vision deterioration if untreated. The social and economic burden of nAMD is significant, as it directly affects independence, quality of life, and healthcare systems.
Over the past decade, treatment…
Mantle Cell Lymphoma Market Projected to Grow at 7.6% CAGR, Reaching USD 4.0 Bil …
Introduction
Mantle Cell Lymphoma (MCL) is a rare and aggressive type of non-Hodgkin's lymphoma (NHL) that arises from B lymphocytes within a region of the lymph node known as the "mantle zone." Although relatively uncommon, MCL represents a significant healthcare challenge due to its complex biology, late diagnosis, and tendency to relapse after treatment. Over the last decade, however, research breakthroughs in molecular biology, targeted therapies, and immuno-oncology have reshaped treatment…
Keratoconus Market Expected to Grow at 7.2% CAGR, Reaching USD 4.3 Billion by 20 …
Introduction
Keratoconus, a progressive eye disorder that causes thinning and bulging of the cornea into a cone-like shape, significantly affects vision and quality of life. Traditionally underdiagnosed, it has now come into greater focus thanks to increased awareness, advances in diagnostic imaging, and new treatment technologies. Rising prevalence among young adults and adolescents, combined with a growing need for early intervention, is driving strong demand in the keratoconus market.
Over the past…
More Releases for MIGS
Rising Prevalence of Glaucoma Spurs Demand for Minimally Invasive Glaucoma Surge …
The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Size and Projected Growth Rate?
The minimally invasive glaucoma surgery (MIGS) devices market size has surged significantly in recent years. It…
The Rising Tide of Minimally Invasive Glaucoma Surgery (MIGS) Devices: A Market …
https://www.alliedmarketresearch.com/minimally-invasive-slaucoma-surgery-MIGS-devices-market
Glaucoma, one of the leading causes of irreversible blindness, has historically been a challenge for patients and healthcare providers. Traditional glaucoma surgeries, while effective, often pose significant risks and require long recovery periods. However, the introduction of Minimally Invasive Glaucoma Surgery (MIGS) devices is transforming the landscape of glaucoma treatment. With the MIGS devices market valued at $298.75 million in 2020 and projected to reach $5,099.38 million by 2030 at…
Leading Growth Driver in the Minimally Invasive Glaucoma Surgery (MIGS) Devices …
What Are the Market Size and Growth Forecast for the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market?
The market size for minimally invasive glaucoma surgery (MIGS) devices has witnessed an exponential surge in recent years. The market is projected to escalate from $0.7 billion in 2024 to $0.9 billion in 2025, hitting a compound annual growth rate (CAGR) of 28.3%. Factors such as heightened consciousness about blindness prevention, substantive investments in…
Market Research Report on Micro Invasive Glaucoma Surgery (MIGS) Devices
The global healthcare industry has witnessed significant advancements in the field of ophthalmology, particularly in the treatment of glaucoma. Micro Invasive Glaucoma Surgery (MIGS) has emerged as a promising minimally invasive alternative to traditional glaucoma surgeries. MIGS devices offer a safer and more efficient approach to managing intraocular pressure (IOP) while minimizing complications and recovery time. This market research report provides valuable insights into the current landscape and future prospects…
NA Micro Invasive Glaucoma Surgery (MIGS) Devices Market Size, Share, Industry, …
The NA Micro Invasive Glaucoma Surgery (MIGS) Devices Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global NA Micro Invasive Glaucoma Surgery (MIGS) Devices market. This report explores all the key factors…
Global Micro Invasive Glaucoma Surgery (MIGS) Devices Market Growth Data Analysi …
This report also researches and evaluates the impact of Covid-19 outbreak on the Micro Invasive Glaucoma Surgery (MIGS) Devices industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Micro Invasive Glaucoma Surgery (MIGS) Devices and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Global Micro Invasive Glaucoma Surgery (MIGS) Devices Market Overview:
The latest report on the…
